DOCSLIB.ORG

Outcome of L-DEP Regimen for Treatment of Pediatric Chronic Active

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Outcome of L-DEP Regimen for Treatment of Pediatric Chronic Active Ma et al. Orphanet J Rare Dis (2021) 16:269 https://doi.org/10.1186/s13023-021-01909-y RESEARCH Open Access Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein–Barr virus infection Honghao Ma1†, Liping Zhang1†, Ang Wei1, Jun Yang1, Dong Wang1, Qing Zhang2, Yunze Zhao1, Sitong Chen2, Hongyun Lian1, Li Zhang1, Chunju Zhou3, Maoquan Qin1, Zhigang Li2*, Tianyou Wang1* and Rui Zhang1* Abstract Purpose: We intended to investigate the clinical features of paediatric patients with chronic active Epstein–Barr virus infection (CAEBV) and to examine the efectiveness of the L-DEP regimen before haematopoietic stem cell transplan- tation (HSCT). Methods: A retrospective analysis was performed on 35 patients with CAEBV at Beijing Children’s Hospital from Janu- ary 2016 to January 2020. The efcacy and adverse events of the L-DEP regimen were evaluated. Results: The median age of the 35 patients was 7.0 years old (range 2.5–17.5 years). Twenty-eight patients achieved a clinical response (80.0%, 22 in clinical CR, 6 in clinical PR) after L-DEP. In terms of virological response, 7 patients (20%) were assessed as having virological CR, and 23 patients (65.7%) had virological PR. Finally, 29 patients underwent allo-HSCT. The median survival time was 18 months (2–50 months). The 3-year overall survival rates in patients treated with chemotherapy only (n 6) and chemotherapy followed by HSCT (n 25) were 33.3% and 75.4%, respectively. After L-DEP 1st treatment and= L-DEP 2nd treatment, the EBV-DNA loads in= blood and plasma were signifcantly reduced compared with those before chemotherapy (median: 4.29 ­105 copies/ml vs. 1.84 ­106 copies/ml, Mann– Whitney U: P 0.0004; 5.00 ­102 copies/ml vs. 3.17 ­103 copies/ml,× Mann–Whitney U; P 0.003;× 2.27 ­105 copies/ml vs. 1.84 ­106= copies/ml, P × 0.0001; 5.00 ­102 copies/ml× vs. 3.17 ­103 copies/ml, P 0.003).= Compared× with the liver and spleen× size before chemotherapy,= the× size of the liver and spleen× shrank signifcantly= after L-DEP 2nd (median 3.8 cm vs. 1.9 cm, P 0.003; 3.8 cm vs. 0 cm, P < 0.008). In addition, after L-DEP treatment, there was no diference in = *Correspondence: [email protected]; [email protected]; [email protected] †Honghao Ma and Liping Zhang have contributed equally to this work 1 Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China 2 Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China Full list of author information is available at the end of the article © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Ma et al. Orphanet J Rare Dis (2021) 16:269 Page 2 of 9 the clinical or virological response rate regardless of HLH status (clinical response: 77.3% vs. 84.6%, P 0.689; virologi- cal response: 90.9% vs. 76.9%, P 0.337). = = Conclusion: The L-DEP regimen is an efective therapy in CAEBV for bridging to allo-HSCT. Keywords: Chronic active Epstein–Barr virus infection, L-DEP, Response, Paediatric Introduction In this study, we treated children with CAEBV with Chronic active Epstein–Barr virus infection (CAEBV) L-DEP regimens and analysed the clinical characteristics, is a rare lymphoproliferative disorder (LPD) that typi- prognostic factors, and efectiveness of the regimens. Te cally presents as persistent infectious mononucleosis-like results showed that the L-DEP regimen is an efective disease and/or haemophagocytic lymphohistiocytosis therapy in CAEBV for bridging to allo-HSCT. (HLH) [1–3]. Tis disease occurs mainly due to infam- mation accompanied by EBV infection of T or NK cells. Patients and methods EBV-infected T or NK cells can proliferate and infltrate Patients clonally into multiple organs, leading to diferent clinical Retrospectively, single-centre data were collected from behaviours from indolent disease to rapidly life-threaten- 35 patients with CAEBV treated at the haematology ing disease. Te clinical manifestations include fever, skin oncology centre of Beijing Children’s Hospital between rashes, hepatomegaly, splenomegaly, lymphadenopathy, January 2016 and January 2020. According to the World liver dysfunction, and higher EBV-DNA load in blood Health Organization (WHO) classifcation of 2016, or plasma [3]. In terms of treatment, allogeneic HSCT children who fulflled all of the following criteria were (allo-HSCT) is the only curative treatment for eliminat- diagnosed with CAEBV: (1) sustained or recurrent IM- ing EBV-infected T or NK cells [4]. Unfortunately, active like symptoms persisting for more than 3 months; (2) disease conditions, which occur at the beginning of the elevated EBV genome load in the peripheral blood (PB) conditioning treatment of allo-HSCT, are signifcantly or the tissue lesion; (3) EBV infection of T or NK cells in associated with poor allo-HSCT outcomes [1, 5]. Tere- the afected tissues or the PB; and (4) exclusion of other fore, to improve the prognosis, patients should receive possible diagnoses: primary infection of EBV (infec- chemotherapy before allo-HSCT to resolve disease activ- tious mononucleosis), autoimmune diseases, congenital ity [1]. immunodefciencies, HIV, and other immunodefcien- However, the response rate of diferent chemotherapy cies requiring immunosuppressive therapies or underly- regimens to CAEBV difers greatly. Many studies have ing diseases with potential immunosuppression [7]. Te proposed diferent chemotherapy regimens, including clinical diagnosis of HLH was based on the HLH-2004 cooling therapy (combination of cyclosporine A, steroids diagnostic criteria [10]. and etoposide), CHOP (cyclophosphamide, doxorubicin, Clinical data, including demographic characteristics, vincristine and prednisolone), and the combination of laboratory fndings, treatment outcomes and mortality, the two (cooling therapy, CHOP, Capizzi and ESCAP), were collected. Written informed consent was obtained but the total response rate of patients is less than 40% from the parents, and the study was approved by the and even as low as 10% [1, 6, 7]. To improve the outcomes Institutional Review Board of Beijing Children’s Hospital, of CAEBV, it is indispensable to establish more efective Capital Medical University. Tis clinical trial assessing chemotherapy. the L-DEP regimen for CAEBV patients was retrospec- In 2016, Wang et al. used PEG-asparaginase, liposomal tively registered (Identifer: ChiCTR1900020574). doxorubicin, etoposide, and high-dose methylpredniso- lone (L-DEP regimen) as salvage therapy for controlling Treatments refractory EBV-related haemophagocytic lymphohistio- All of the patients were treated with L-DEP regimens cytosis (EBV-HLH) and achieved a signifcant EBV-DNA after diagnosis. Te L-DEP regimen included PEG- decrease and good outcome (OR: 85.7%) [8]. In 2020, asparaginase (2000 U/m2, day 5), liposomal doxorubicin Zhao et al. showed that the L-DEP regimen could also (25 mg/m2, day 1), etoposide (100 mg/m2 once a week, beneft paediatric patients with refractory EBV-HLH, days 1, 8 and 15), and methylprednisolone (2 mg/kg, with an OR rate of 61.5% [9]. Since both EBV-HLH and days 1–7; 1 mg/kg, days 8–14; 1 mg/kg, and tapering, CAEBV are EBV-related LPDs, and CAEBV is often asso- days 15–21). Te L-DEP regimen was used for at least ciated with HLH, we speculate that the L-DEP regimen 2 courses and up to 3 courses. Te treatment response could be benefcial to children with CAEBV. was evaluated after 3 weeks (L-DEP 1st) and/or 6 weeks Ma et al. Orphanet J Rare Dis (2021) 16:269 Page 3 of 9 (L-DEP 2nd) [8]. Once a patient achieved remission, allo- between two groups, respectively. Te chi-square test HSCT was recommended. was used to determine whether there were diferences in After chemotherapy, a total of 29 patients under- qualitative variables between groups. Survival analyses went allo-HSCT, and the other 6 patients did not were carried out by Kaplan–Meier analysis, and difer- undergo HSCT because of fnancial problems or disease ences in OS were compared with the two-tailed log-rank deterioration. test. A P value < 0.05 was considered statistically signif- cant. GraphPad Prism software, version 6.0 (Inc., San Evaluation of response to L‑DEP regimen Diego, CA, USA), was used to draw graphs. Te outcomes of the L-DEP regimen were evaluated and classifed as follows.
Load more

Recommended publications
  • Puritis in Cats
    Clinical Approach to the Pruritic Cat Dr Robert Hilton BVSc(Hons) MACVSc CertVD MRCVS When dealing with cats with skin disease, it is important to understand that cats are not small dogs. The same cause may elicit different reaction patterns in different cats. Cats were worshipped as gods in ancient Egypt, and have not quite got over the fact. They are often difficult to pill, resent bathing, fail to eat elimination diets, hunt and steal food and love to remove topical medication by licking as soon as it is put on. The principal causes of feline pruritus are listed below: Common Allergies and ectoparasites − Flea bite allergy − Food allergy (and on rare occasions, non immune-mediated adverse food ) reactions − Atopic dermatitis − Mosquito hypersensitivity − Reactions to mites ( Otodectes, Cheyletiella, Notoedres, Sarcoptes ) Infections − Bacterial pyoderma (almost always secondary) − Dermatophytosis − Feline Herpes infection (especially nose and face) − Malassezia (especially Rex and Sphinx) Less Common Ectoparasites − Feline demodecosis (The contagious short-bodied D. gatoi is commonly recognised in Europe and North America) − Lice − Infestation with Trombicula spp Immune mediated disease − Pemphigus foliaceus − Drug reactions − Sebaceous adenitis − Lymphocytic mural folliculitis Neoplasia − Epitheliotropic lymphoma − Squamous cell carcinoma (common neoplasm, uncommonly pruritic) − Feline mast cell tumours Idiopathic − Psychological pruritus − Idiopathic facial dermatitis (dirty face disease) of Persian cats (Adapted from Noli and Scarampella (2004)) Same aetiology Same protocol Same treatment Manifestations of feline allergic disease. Any one or more of the following: Milliary dermatitis Eosinophilic plaque Eosinophilic granuloma Linear plaque/granuloma Over grooming syndrome Head and neck pruritus Urticaria pigmentosa Rodent ulcer Milliary dermatitis presents as multiple small crusted papules on any part of the body.
    [Show full text]
  • Conflicts Between People and the Florida Black Bear
    JULY/AUGUST 2019 Staining Pests of Black Olive Trees | New Turf Disease UF Urban Lab, From Research PESTPRO To Products From Pest Management Education, Inc. to Landscape and Pest Managers Late-Season Defoliators On Hardwood Trees Conflicts Between People and the Florida Black Bear Port Orange, FL 32127-5801 FL Orange, Port July / August 2019 Blvd. Hill Nob 5814 Pest Management Education, Inc. | PestEducation, Pro 1 Management Pest ® TAURUSThey know a lot about flavor.SC Fipronil 9.1% Guaranteed Results That’s why it’s important to keep your menu fresh with Advion® Evolution Cockroach Gel Bait. Its enhanced bait matrix attracts even the toughest cockroaches while increasing feeding and speed of kill. Learn more about Advion Evolution and the benefits you get as part of the PestPartnersSM 365 program at SyngentaPMP.com/AdvionEvolution. 10 A new SecureChoice℠ assurance program featuring Advion Evolution is coming soon! YEAR Promise of Protection ControlSolutionsInc.com Taurus is a registered trademark of Control Solutions, Inc. Adama.com Control©2019 Syngenta. Solutions, Important: Inc. Always read and follow label instructions. Some products may not be registered for sale or use in all statesThis product or may not be registered in all states, Innovationcounties and/or you maycan haveapply. state-specificFind Us useOn requirements. Please check with your local extension service to ensure registration andplease proper check the use. CSI website for registration information. Advion Pest®, For Life ProUninterrupted™, | July PestPartners / AugustSM, SecureChoice℠,2019 the Alliance Frame, the Purpose Icon and the Syngenta logo are trademarks or service2 marks of a Syngenta Group Company. Syngenta Customer Center: 1-866-SYNGENT(A) (796-4368).
    [Show full text]
  • PRICK TESTING in INSECT BITE REACTION Dissertation Submitted
    PRICK TESTING IN INSECT BITE REACTION Dissertation submitted to The Tamil Nadu Dr. M.G.R Medical University, Chennai In fulfilment of the requirements for the award of the degree of Doctor of Medicine in Dermatology, Venereology and Leprology Under the guidance of Dr. SHANMUGA SEKAR .C, MD., Department of Dermatology, Venereology and Leprology PSG INSTITUTE OF MEDICAL SCIENCES & RESEARCH, COIMBATORE THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY, CHENNAI, TAMILNADU MAY 2018 CERTIFICATE This is to certify that the thesis entitled “PRICK TESTING IN INSECT BITE REACTION” is a bonafide work of Dr. IYSHWARIYA SIVADASAN done under the direct guidance and supervision of Dr.C.R. SRINIVAS, MD and Dr. SHANMUGA SEKAR .C, MD, in the department of Dermatology, Venereology and Leprology, PSG Institute of Medical Sciences and Research, Coimbatore in fulfillment of the regulations of The Tamil Nadu Dr.MGR Medical University for the award of MD degree in Dermatology, Venereology and Leprology. Dr. REENA RAI Dr. RAMALINGAM Professor & Head of Department DEAN Department of DVL DECLARATION I hereby declare that this dissertation entitled “PRICK TESTING IN INSECT BITE REACTION” was prepared by me under the direct guidance and supervision of Dr.C.R.SRINIVAS, MD and Dr. SHANMUGA SEKAR C., MD, PSG Institute of Medical Sciences and Research, Coimbatore. The dissertation is submitted to The Tamil Nadu Dr. MGR Medical University in fulfillment of the University regulation for the award of MD degree in Dermatology, Venereology and Leprology. This dissertation has not been submitted for the award of any other Degree or Diploma. Dr. IYSHWARIYA SIVADASAN CERTIFICATE BY THE GUIDE This is to certify that the thesis entitled “PRICK TESTING IN INSECT BITE REACTION” is a bonafide work of Dr.
    [Show full text]
  • List of Original Publications
    ARI KARPPINEN Antihistamines in the Treatment of Mosquito-Bite Allergy ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Medicine of the University of Tampere, for public discussion in the small auditorium of Building B, Medical School of the University of Tampere, Medisiinarinkatu 3, Tampere, on October 26th, 2001, at 13 o’clock. Acta Universitatis Tamperensis 841 University of Tampere Tampere 2001 ACADEMIC DISSERTATION University of Tampere, Medical School Tampere University Hospital, Department of Dermatology and Venereology Finland Supervised by Reviewed by Professor Timo Reunala Docent Antti Lauerma University of Tampere University of Helsinki Professor Ilari Paakkari University of Helsinki Distribution University of Tampere Sales Office Tel. +358 3 215 6055 P. O. B o x 617 Fax +358 3 215 7685 33014 University of Tampere [email protected] Finland http://granum.uta.fi Cover design by Juha Siro Printed dissertation Electronic dissertation Acta Universitatis Tamperensis 841 Acta Electronica Universitatis Tamperensis 136 ISBN 951-44-5190-2 ISBN 951-44-5191-0 ISSN 1455-1616 ISSN 1456-954X http://acta.uta.fi Tampereen yliopistopaino Oy Juvenes Print Tampere 2001 To my family Contents Abbreviations..................................................................................................................................................... 4 List of original publications............................................................................................................................... 5 A. INTRODUCTION
    [Show full text]
  • Eosinophilic Granuloma Complex
    Eosinophilic Granuloma Complex in Cats and Eosinophilic Granulomas in Dogs Basics OVERVIEW • Cats—“eosinophilic granuloma complex” often is a confusing term used for four distinct syndromes: (1) “eosinophilic plaque” (circumscribed, raised, round to oval lesions that frequently are ulcerated; usually located on the abdomen or thighs; lesions contain a type of white blood cell, called an eosinophil); (2) “eosinophilic granuloma” (a mass or nodular lesion containing eosinophils; usually found on the back of the thighs, on the face, or in the mouth); (3) “indolent ulcer” (circumscribed, ulcerated lesions; most frequently found on upper lip); (4) allergic miliary dermatitis (skin inflammation characterized by numerous, small, crusty bumps); the four syndromes are grouped together as “eosinophilic granuloma complex” primarily according to their clinical similarities, their frequent simultaneous development and tendency to recur, and their positive response to treatment with steroids • Dogs—”eosinophilic granulomas” are rare; not part of the eosinophilic granuloma complex; specific differences from cats are presented in the following information • “Eosinophilic” refers to eosinophils, a type of white-blood cell usually involved in allergic responses • “Granuloma” is a large inflammatory nodule or solid mass • “Complex” is a group of signs or diseases that have an identifiable characteristic that makes them similar in some fashion GENETICS • Several reports of related affected individuals and a study of disease development in a colony of cats
    [Show full text]
  • Decrease of Mosquito Salivary Gland Proteins After a Blood Meal: an Implication for Pathogenesis of Mosquito Bite Allergy
    Decrease of Mosquito Salivary Gland Proteins after a Blood Meal: An Implication for Pathogenesis of Mosquito Bite Allergy Padet Siriyasatien MD, PhD*, Kuntida Tangthongchaiwiriya MSc* Kanyarat Kraivichian MD*, Surang Nuchprayoon MD, PhD* Apiwat Tawatsin MAppl Sc**, Usavadee Thavara PhD** * Department of Parasitology, Faculty of Medicine, Chulalongkorn University ** National Institute of Health, Department of Medical Sciences, Nonthaburi SalivOlY gland protein profiles of Aedes aegypti (L) and Culex quinquefasciatus (Say) pre- and post- bloodfeeding were analyzed. SDS-PAGE studies before blood feeding of Ae. aegypti demonstrated 8 major polypeptide bands of 20, 35, 37, 42, 45, 47, 70 kDa and a high molecular weight band> 118 kDa, whereas those ofCx. quinquefasciatus demonstrated 9 major polypeptide bands of 20, 26, 36, 38, 45, 47, 49 kDa and 2 high molecular weight bands> 118 kDa. After a blood feeding, salivary gland polypeptides of Ae. aegypti at 35,37,45,47, 70 kDa and high molecular weight band> 118 kDa were depleted, while the polypeptide bands of 20, 26, 36, 38 kDa were depleted in Cx. quinquefasciatus. The presented study suggests that these major polypeptides were introduced into vertebrate hosts when a mosquito took a blood meal, Further investigation in molecular, biochemical and immunological aspects of these salivOlY gland polypeptides may provide information for better understanding in the role of these proteins in mosquito bite allergy. Keywords: Mosquito bite allergy, Aedes aegypti, Culex quinquefasciatus, Mosquito saliva!)' gland protein J Med Assoc Thai 2005; 88(Suppl 4): S255-9 Full text. e-Journal: http://www.medassocthai.orgljournal Dennal allergyto mosquitobites isa common salivary glands of several mosquito species have been problemworldwide.
    [Show full text]
  • Rupatadine for the Treatment of Allergic Rhinitis and Urticaria: a Look at the Clinical Data
    Review: Clinical Trial Outcomes For reprint orders, please contact [email protected] 4 Review: Clinical Trial Outcomes Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data Clin. Invest. The second-generation antihistamine rupatadine is a new long-acting and Erminia Ridolo*,1, Marcello non-sedating drug that exerts a potent dual-antagonist activity towards the histamine Montagni1, Filippo Fassio2, H1 receptor and the PAF receptor. Rupatadine is prescribed for the relief of symptoms Ilaria Massaro3, Oliviero 4 5 of seasonal and perennial allergic rhinitis and in the treatment of chronic urticaria. Rossi , Cristoforo Incorvaia & Giorgio Walter Canonica6 Clinical trials have shown that rupatadine, which shows a rapid onset of action and 1Department of Clinical & Experimental prolonged duration of activity, is effective and well tolerated. Safety data indicate Medicine, University of Parma, Parma, Italy that rupatadine does not affect the cardiovascular system, without relevant changes 2Department of Biomedicine, Immunology in the corrected QT interval, or significantly affect psychomotor activity at the doses & Cell Therapies Unit, AOU Careggi, used in clinical practice. Here, we review the efficacy and safety profile of rupatadine University of Florence, Italy 3 in patients with allergic rhinitis and urticaria. Centre for Research, Transfer & High Education DENOTHE, University of Florence, Florence, Italy Keywords: allergic rhinitis • chronic urticaria • histamine • platelet-activating factor 4Department of Biomedicine, • rupatadine Immunoallergology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy The new antihistamine rupatadine is a potent, distinct clinical entities both respond to anti- 5Pulmonary Rehabilitation Unit, ICP orally active, non-sedating, long-acting antag- histamine treatment. This review focuses on Hospital, Milan, Italy onist of both histamine H1 receptors and PAF the clinical characteristics of rupatadine and 6Allergy & Respiratory Diseases Clinic, receptors.
    [Show full text]
  • Chronic Active EBV Infection: the Experience of the Samsung Medical Center in South Korea 11
    Bol Med Hosp Infant Mex. 2016;73(1):10---17 www.elsevier.es/bmhim CLINICAL CASE Chronic active EBV infection: the experience of the Samsung Medical Center in South Korea ∗ Tae-Hee Lee, Young-Hyeh Ko Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea Received 11 November 2015; accepted 3 December 2015 Available online 1 February 2016 KEYWORDS Abstract Epstein-Barr virus; Background: Chronic active EBV infection (CAEBV) of T-cell or NK-cell type is an EBV+ polyclonal, Children; oligoclonal or often monoclonal lymphoproliferative disorder (LPD) recognized as representing Chronic active the spectrum of EBV-associated T-cell and NK-cell LPD with different clinical presentations; infection; one systemic and two cutaneous disorders including hydroa vacciniforme-like T-cell LPD and NK lymphocytosis; mosquito bite hypersensitivity. The systemic form of the disease is characterized by fever, Mosquito-bite persistent hepatitis, hepatosplenomegaly and lymphadenopathy, which shows varying degrees hypersensitivity of clinical severity depending on the immune response of the host and the EBV viral load. Case reports: We described the clinicopathological findings of two children with CAEBV with a brief review of the literature. Conclusions: Recognition of the disease is important for adequate management of the patient. EBV analysis should be included in the principal diagnostic tests for febrile children. © 2015 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access
    [Show full text]
  • Systemic Epstein-Barr Virus–Positive T-Cell Lymphoma of Childhood
    CASE REPORT Systemic Epstein-Barr Virus–Positive T-cell Lymphoma of Childhood Qiong Wu, MD; Faliang Ren, MD; Dirk M. Elston, MD relapsing course, accompanied by rigors but without con- PRACTICE POINTS vulsions or cognitive changes. At times, the patient had • Systemic Epstein-Barr virus (EBV)–positive T-cell nasal congestion, nasal discharge, and cough. He also had lymphoma of childhood is a fulminant illness with a a transient eruption on the back and hands as well as an predilection for Asians and indigenous populations indurated red nodule on the left forearm. from Mexico and Central and South America. In most Before the patient was hospitalized, antibiotic therapy patients, the disease has an aggressive clinical course was administered by other physicians, but the condition of with high mortality. fever and oral ulcerscopy did not improve. After the patient was • The disease often is complicated by hemophagocytic hospitalized, new tender nodules emerged on the scalp, syndrome, coagulopathy, sepsis, and multiorgan fail- buttocks, and lower extremities. New ulcers also appeared ure. When these severe complications are absent, the on the palate. prognosis might be better. History—Two months earlier, the patient had presented • In situ hybridization for EBV-encoded RNA and for withnot a painful perioral skin ulcer that resolved after being T-cell receptor gene rearrangements is an important treated as contagious eczema. Another dermatologist tool to establish the diagnosis as well as for treatment previously had considered a diagnosis of hand-foot-and- options and predicting the prognosis. Domouth disease. The patient was born by normal spontaneous vaginal delivery, without abnormality.
    [Show full text]
  • EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts
    pathogens Review EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts Stefan D. Dojcinov 1 ID , Falko Fend 2 and Leticia Quintanilla-Martinez 2,* ID 1 Department of Cellular Pathology, University Hospital of Wales, Cardiff CF14 4XW, UK; [email protected] 2 Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, 72076 Tübingen, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-7071-2082979 Received: 4 February 2018; Accepted: 5 March 2018; Published: 7 March 2018 Abstract: The contribution of Epstein-Barr virus (EBV) to the development of specific types of benign lymphoproliferations and malignant lymphomas has been extensively studied since the discovery of the virus over the last 50 years. The importance and better understanding of the EBV-associated lymphoproliferative disorders (LPD) of B, T or natural killer (NK) cell type has resulted in the recognition of new entities like EBV+ mucocutaneous ulcer or the addition of chronic active EBV (CAEBV) infection in the revised 2016 World Health Organization (WHO) lymphoma classification. In this article, we review the definitions, morphology, pathogenesis, and evolving concepts of the various EBV-associated disorders including EBV+ diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), EBV+ mucocutaneous ulcer, DLBCL associated with chronic inflammation, fibrin-associated DLBCL, lymphomatoid granulomatosis, the EBV+ T and NK-cell LPD of childhood, aggressive NK leukaemia, extranodal NK/T-cell lymphoma, nasal type, and the new provisional entity of primary EBV+ nodal T- or NK-cell lymphoma.
    [Show full text]
  • Total Ige, Mosquito Saliva Specific Ige and CD4+ Count in HIV-Infected Patients with and Without Pruritic Papular Eruptions
    Original article Total IgE, mosquito saliva specific IgE and CD4+ count in HIV-infected patients with and without pruritic papular eruptions Sukhum Jiamton,1 Taniya Kaewarpai,2 Pattama Ekapo,3 Kanokvalai Kulthanan,1 Saowalak 4 5 5 Hunnangkul, John J. Boitano and Sirichit Wongkamchai Summary significantly higher than for those without PPE. A comparison of the mean arbitrary scores of the Background: Pruritic Papular Eruption (PPE) is specific IgE in HIV patients, with and without a skin disorders found in HIV infected patients. PPE, was non-significant (p = 0.152). However, However, the exact etiology of PPE is not 44% (11/25) of the HIV patients with PPE had an documented. It has been suggested that PPE arbitrary score above the mean score of mosquito might result from arthropod bites. bite allergic subjects, as compared to only 3.3% Objective: The aim of this study was to (2/60) of HIV patients without PPE. investigate those factors in the HIV patient Conclusions: It may be concluded that the contributing to the occurrence of PPE, including etiology of PPE in the HIV patient may be specific IgE against mosquito saliva allergens, heterogeneous or multi-causal with allergic total IgE, CD4 cell counts and their associations. responses to the mosquito saliva allergen being Methods: Specific IgE against saliva allergens of only partially responsible. (Asian Pac J Allergy Cx. quinquefasciatus mosquito was measured in Immunol 2014;32:53-9) 25 HIV patients with PPE and in 60 HIV without Key words: pruritic papular eruptions, HIV, PPE by a time-resolved fluorescence immunoassay mosquito saliva allergens, specific IgE, total IgE (TRIFA).
    [Show full text]
  • June 2016 Newsletter
    To the Greatest Father of all, Happy Father’s Day to our Heavenly Father! THE FRIENDLY CONNECTION NEWSLETTER FRIENDLY TEMPLE CHURCH OF GOD IN CHRIST “W HERE EVERYBODY IS SOMEBODY AND JESUS CHRIST IS LORD !” 16570 “E” STREET VICTORVILLE, CA 92395 -- (760) 245-8788 DR. ROGER THOMAS, PASTOR - DR. MARIE THOMAS, FIRST LADY June 2016 TURN BACK TO GOD IN 2016 Volume 7, Issue 6 and wait patiently on Him, for He is the author and finisher of our faith. Hebrews 12:1-2 Published Monthly ================================================================================================================================================================================================================================================ ================= “… let us lay aside every weight, and the sin which doeth easily Newsletter Staff: beset us, and run with patience the race that is set before us.” EDITOR-IN-CHIEF FROM THE PASTOR’S DESK Deborah “A DOLLAR’S WORTH JUST WON’T DO” continued Thompson-Ealy EPHESIANS 5:18 ASSOCIATE EDITOR: “And be not drunk with wine, wherein is excess; Evangelist Henrietta but be filled with the Spirit…” Givens We are in church to become spiritually stronger so that we can STAFF MEMBERS: help somebody else get saved and become stronger in the Lord. If Elder Larry Ealy you have been saved for many years and no one else in your family Bettie Young is saved, it’s time to question your salvation, or the kind of life you Sherease Durden have been living before your family and before God. Mary Jackson Many people in the church have lost their JOY in the Lord because COLUMNISTS: all they wanted was “a dollar’s worth”. Remember, if you don’t Charmayne Moore put anything in to worship, you won’t get anything out of it.
    [Show full text]